GI Windows and Joslin Diabetes Center Agree to a Memorandum of Understanding

BOSTON – (June 4, 2015) – GI Windows and Joslin Diabetes Center have signed a Memorandum of Understanding (MOU) formalizing their mutual commitment to explore avenues for collaboration, using the GI Windows technology to treat patients with type 2 diabetes.

This non-exclusive MOU was developed after meetings between the GI Windows’ team and Osama Hamdy, M.D., Ph.D, FACE, Medical Director of the Obesity Clinical Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School. The agreement is a step towards establishing a collaboration with GI Windows that aligns with Joslin’s mission of preventing, treating and curing diabetes in the world.

“The collaboration with GI Windows illustrates Joslin’s commitment to study new technologies and assess their ability to make an impact on diabetes prevention and treatment,” said Dr Hamdy. He added, “The early results of the GI Windows technique are very interesting. I think GI Windows’ innovative technology may emerge as an important tool to combat type 2 diabetes.”

In current metabolic surgical procedures, small bowel bypasses are associated with durable weight loss and co-morbidity resolution. GI Windows has created a technology that can create a surgical-quality anastomosis, bypassing portions of the GI tract, but without incisions, staples, or any long-term foreign body. GI Windows has already completed a small clinical study in Europe that is showing promising results.  

James Wright, CEO of GI Windows, commented on the GIW-Joslin MOU: “We are thrilled to collaborate with Dr. Hamdy and Joslin Diabetes Center.  Joslin brings world-class experience and insight to ways our technology may impact the treatment of patients. Together, we hope to help advance diabetes care worldwide.”

About G.I. Windows, Inc.

GI Windows is an early-stage medical device company developing an incision-less anastomotic system that can be used to create non-surgical therapies to treat type-2 diabetes.  The company’s technology is designed to enable durable, intestinal bypasses to address chronic diseases, such as Type-2 Diabetes and Obesity, without the cost and invasiveness of surgical interventions. 

Contact: James Wright, 781-436-4375 ext.1601